We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PhRMA’s board of directors is expected to weigh in on the contentious issue of direct-to-consumer (DTC) advertising this month as it mulls an industrywide voluntary DTC code of conduct.
More than 95 percent of the underlying causes of adverse events can be traced to inadequate management systems rather than to personnel performance issues, says an industry expert.
The U.S. Patent and Trademark Office’s (PTO) recent preliminary rejection of one of Pfizer’s patents covering cholesterol-lowering drug Lipitor may not necessarily open the door to generic versions of the drug.
The Health Industry Group Purchasing Association (HIGPA) recently fired back at allegations made by the Medical Device Manufacturers Association (MDMA) that certain group purchasing organizations (GPOs) abuse legal exceptions allowed by an anti-kickback safe harbor provision. Currently, the safe harbor allows GPOs to collect administrative fees from medical device manufacturers in exchange for administering purchasing contracts with hospitals.
Medical technology association AdvaMed recently called upon Congress to create financial incentives and establish a safe harbor provision to help kick-start a health information technology (HIT) initiative it says will "revolutionize the healthcare delivery system."
When implementing corrective and preventive action measures (CAPA), pharmaceutical firms must look beyond product issues and focus on quality, process and systemic issues, according to an industry expert.
The FTC is weighing the merits of conducting a study on the competitive effects of authorized generics, but it is looking for input from drugmakers before deciding how to proceed on the matter, an agency official told a recent industry conference.